Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
29 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Hospital in Arizona
Phoenix, Arizona, United States
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Los Angeles General Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Uc Irvine Health/chao Family Comprehensive Cancer Center
Orange, California, United States
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- Uchealth University of Colorado Hospital
Aurora, Colorado, United States
- Um Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
- Um Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, United States
- Emory Saint Joseph'S Hospital
Atlanta, Georgia, United States
- Emory University Hospital Midtown
Atlanta, Georgia, United States
- Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
- Northwestern University
Chicago, Illinois, United States
- Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Laura and Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- Vanderbilt University/ingram Cancer Center
Nashville, Tennessee, United States
- M D Anderson Cancer Center
Houston, Texas, United States
- University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
- Huntsman Cancer Institute/university of Utah
Salt Lake City, Utah, United States
- University of Virginia Cancer Center
Charlottesville, Virginia, United States
- University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Dec 2021
- Primary completion
- 2 Jan 2024
- Completion
- 29 Apr 2026
- Last update posted
- 23 May 2025
- Registered enrollment
- 57
- Registry id
- NCT04941287
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.